Tema Oncology ETF(CANC.US)

BMS reports positive results in Phase III SCOUT-HCM trial for oHCM

Bristol Myers Squibb (BMS) has reported positive results from the Phase III SCOUT-HCM trial for Camzyos (mavacamten) in treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adolescents aged 12 to under 18. The trial met its primary endpoint, showing significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at week 28 compared to placebo. Safety data remained consistent with adult profiles, and BMS plans to present comprehensive results at a medical congress. The study continues with active treatment and long-term extension phases.

Bridgebio Pharma | 8-K: FY2025 Q4 Revenue Misses Estimate at USD 146 M

Revolution Medicines Showcases Pipeline Progress and Phase 3 Trials Targeting RAS-Driven Cancers

Revolution Medicines Inc. has updated its clinical pipeline for RAS-addicted cancers, reporting over 2,500 patients treated with RAS(ON) inhibitors. The company is conducting or planning eight Phase 3 trials for drugs including daraxonrasib, zoldonrasib, elironrasib, and RMC-5127, targeting pancreatic, non-small cell lung, and colorectal cancers. Daraxonrasib has shown promising results in monotherapy and in combination therapies. Ongoing trials for non-small cell lung cancer and completed enrollment for pancreatic cancer are noted. The full presentation is available via a provided link.

BridgeBio Pharma Highlights Pipeline Progress and Patient Impact in New Corporate Presentation

BridgeBio Pharma Inc. has released a corporate presentation outlining its pipeline and strategy, focusing on first-in-class therapies for genetic diseases. The company holds an 18.2% stake in BridgeBio Oncology Therapeutics and a 27.5% stake in GondolaBio. Its pipeline includes approved therapies like acoramidis for ATTR-CM, impacting over 8,500 patients and representing a market opportunity over $20 billion. With 15 active clinical trials and a commitment to efficient medicine advancement, BridgeBio emphasizes rapid decision-making and lean operations. The full presentation is accessible via a provided link.

Here's How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years

Revolution Medicines (NASDAQ:RVMD) has outperformed the market by 13.22% annually over the past 5 years, yielding an average annual return of 26.1%. With a market cap of $22.91 billion, a $100 investment in RVMD five years ago would now be worth $307.60, based on the current price of $118.50. This highlights the significant impact of compounded returns on investment growth over time.